Abstract

INFLAMMATORY RESPONSE TO DIABETIC MEDICATIONS IN PATIENTS WITH AND WITHOUT DIABETIC NEPHROPATHY

Madi M Al Sahlawee, Raeed Abd Ali Shreef, Najah R Hadi, Dina A Jamil,Lachlan Smith, *Hayder A Al-Aubaidy

ABSTRACT

Aim: This study was conducted to compare the effects of diet, glibenclamide, and metformin on the inflammatory markers in diabetic patients with and without nephropathy. Materials and Methods: Ninety participants were recruited from the diabetic out clinic in Al- Sadder City Center, Al-Najaf, Iraq. Participants were divided into three groups: the diabetic group with nephropathy (DN=45 participants), diabetic group without nephropathy (DNN=24 participants) and the normal control group (Control= 21 participants). All the diabetic participants were subdivided into four categories based on the treatment modalities 1- DIET subgroup: participants with Diet regimes. 2- GL subgroup: Participants on Glibenclamide (Daonil). 3- MET subgroup: Patients on Metformin (Gloucophage). 4- MET+GL subgroup: Patients on Glibenclamide +Metformin. Blood was taken to measure a series of biochemical markers. Results: There was a significant increase in all of the inflammatory markers in the DN group compared to the DNN group (p<0.05) and the control (p<0.01) groups. In addition, patients on Metformin had significantly lower levels of the inflammatory markers compared to the other 3 subgroups (p<0.05). Conclusion: The study concluded a significant elevation in markers of inflammation in diabetic nephropathy compared to the diabetic non nephropathy; the lowest level of these markers of inflammation was seen in patient on metformin therapy.

Keywords: Diabetic nephropathy, Inflammation, Diabetic pharmacological therapy.